

SHARED CARE FRAMEWORK APC BOARD DATE: 27 SEP 2017

MERCAPTOPURINE

1. Background	The thiopurines (azathioprine and mercaptopurine) are immuno-modulatory agents used to induce and maintain remission in IBD. Although unlicensed to treat these indications, their use is widely established in inflammatory bowel disease and is recommended for use in IBD by European (ECCO) and UK (BSG) guidelines for the management of IBD.
	Mercaptopurine is used only for inflammatory bowel diseases when patients are unable to tolerate azathioprine.
	Indications, dose adjustments and monitoring requirements for disease modifying drugs (DMDs) (licensed and unlicensed indications) included in this Framework are in line with national guidance published by the British Society for Rheumatology 2017. N.B. Mercaptopurine is not included in these 2017 guidelines, but monitoring requirements in this document are in line with those included for azathioprine.
2. Licensed Indications	N/A
3. Locally agreed off-label use	Inflammatory Bowel Disease
5. Locally agreed on-laber use	 Rarely used by rheumatology as an alternative to azathioprine
4. Initiation and ongoing dose regime	Transfer of monitoring and prescribing to Primary care is normally after 3 months
	The duration of treatment will be determined by the specialist based on clinical response and tolerability.
	Dose is variable and will be decided by the clinical team
	initiating treatment. Clinical response may not be evident
	before 6 weeks and may take up to 3 months.
	Lower doses are required in severe renal or hepatic
	impairment, or frail older people.
	The initial oral dose of mercaptopurine is usually 25mg once daily and is gradually increased by 25mg increments to a maintenance dose of $1 - 1.5$ mg/kg daily. Doses are generally determined by metabolite monitoring.

Adapted with permission from Pan Mersey APC version: 1.2

Review date: September 2020

(or earlier if there is significant new evidence relating to this recommendation)

	initiating specialist unle and agreed with the prin Dose increases should be ALT and/or AST and albu	e monitored by FBC creatinine/ eGFR, min every 2 weeks for 6 weeks after
		evert back to previous schedule.
	specialist.	
5. Baseline investigations, initial monitoring and dose titration to be undertaken by specialist	AST, albumin.Baseline thiopurinVaccinations again recommended.	P, FBC, creatinine/ eGFR, ALT and /or e methyltransferase (TPMT) inst pneumococcus and influenza are (Zostavax) is recommended as per
	 the JCVI for eligib Specialist to highling GP of the decision need to give the signal to give the signal to give the signal to add the patient Patients should be influence DMD 	le patients. ight in the first clinic letter notifying the in to initiate DMDs that the GP will hingles vaccine if the patient is older I the pneumococcal vaccine if this has given. The GP should also be advised to the influenza vaccine list. e assessed for comorbidities that may
	 every 2 weeks un Once on stable do ALT and /or AST a 	GFR, ALT and /or AST and albumin til on stable dose for 6 weeks; ose, monthly FBC, creatinine/ eGFR, and albumin for 3 months
	indications)	different for gastroenterology
6. Ongoing monitoring	Monitoring	Frequency
requirements to be undertaken by primary care.	FBC, Creatinine/ eGFR, ALT and/or AST, Albumin CRP and ESR (rheumatology patients only)	Every 12 weeks or more frequently in patients at higher risk of toxicity as advised by the specialist team. The exact frequency of the monitoring to be communicated by the specialist in all cases. (Including patients heterozygous of TMPT)

N.B. For <u>Rheumatology patients</u> <u>only - under the care of St</u> <u>Helens and Knowsley Hospitals</u> : GP to choose whether they are monitored under Option 1 or Option 2	 Option 1: GP to prescribe DMARD while monitoring undertaken via computerised Rheumatology Monitoring System (RMS). For patients with GPs who have access to Whiston pathology ICE system – results will be available via ICE For patients with GPs who do not have access to Whiston ICE, patients will be provided with blue record card of results which they will be advised to be made available to GP when writing prescription. N.B. Option 1 will be implemented by the Rheumatology Team if the patient's GP has not responded to the request for shared care after 21 days Option 2: GP to prescribe DMARD and monitoring to be undertaken via GP surgery. 	
7. Pharmaceutical aspects	Route of administration	Mercaptopurine 50mg tablets
	Formulation	Tablets may be taken with food or on an empty stomach, but patients should standardise the method of administration. The dose should not be taken with milk or dairy products
	Administration details	Mercaptopurine is also available as an oral suspension <i>Xaluprine</i> ® but the tablets and oral suspension are not bioequivalent. Haematological monitoring is advised when switching formulations
	Other important information	MHRA Safety Alert: <u>Recent drug-</u>
8. Contraindications		name confusion mercaptopurine or to any other
Please note this does not replace the Summary of Product Characteristics (SPC) and should be read in conjunction with it.	component of thePrevious mercapt	preparation opurine-induced pancreatitis ictivity (Homozygous recessive):
9. Significant drug interactions	the consultant for advice is given concomitantly with mercaptopurine should be	allopurinol, refer the patient back to and a dose adjustment. If allopurinol th mercaptopurine, the dose of e reduced to 25 % of the original dose.
	Product Characteristics.	
	Seek advice from the initi concerns about interactio	ating Specialist if there are any ns.
10. Adverse Effects and	Result	Action
managements	Abnormal bruising or severe sore throat	Stop drug until FBC results available, contact Specialist Nurse (SN)
	Fall in WCC <3.5 x 10 ⁹ /I	Stop drug. Contact SN
	Fall in neutrophils <1.6 x 10 ⁹ /l	
	Fall in platelets <140 x 10 ⁹ /l	

	Increased MCV >105f/I	Check folate, B12 & TSH. Treat if results are abnormal, contact SN for advice and management if normal.
	Unexplained reduction in albumin <30g/l	Stop drug. Contact SN
	Abnormal LFTs – AST or ALT> 100U/I	Stop drug. Contact SN
	Rash:	Stop drug and contact SN.
	Mouth ulcers:	Stop drug and contact SN.
	Acute abdominal pain	Check serum amylase. Consider pancreatitis.
	Increase in serum creatinine >30% over period of 12 months or less OR decline in eGFR > 25%	Contact specialist nurse if there is new or unexplained renal impairment
11. Advice to patients and carers	benefits and risks of treat	el the patient with regard to the tment and will provide the patient with and advice, including patient dividual drugs.
12. Pregnancy and breast feeding	Compatible throughout pl careful assessment of ris Compatible with breastfe	
	Compatible with paternal	exposure
	(BSR & BHPR guideline on p breastfeeding)	prescribing in pregnancy and
13. Specialist contact information	See Appendix 2	
14. Additional information		ansferred from one specialist to another, a new shared care npleted.
15. References	BSR monitoring guideline	
16. To be read in conjunction	1. Policy for Shared	
with the following documents.	2. Shared care agree	
		s are initiated, one shared care
	agreement ionn should b	e completed for all relevant drugs.

Appendix 1

Policy for Shared Care

Shared care is only appropriate if it provides an optimum solution for the patient and it meets the criteria outlined in the Shared Care section of the Pan Mersey **Definitions and Criteria for Categorisation of Medicines in the Pan Mersey Formulary** document.

Before prescribing responsibilities are transferred to primary care:

- Prescribing responsibility will only be transferred when the consultant and the patient's GP agree that the patient's condition is stable.
- All information required by the shared care framework for the individual medicine has been provided to the patient's GP.
- Patients will only be referred to the GP once the GP has agreed to the Shared Care Agreement and returned signed copies.

Inherent in any shared care agreement is the understanding that participation is at the discretion of the GP, subject to the availability of sufficient information to support clinical confidence.

Specialist Responsibilities in Shared Care

- To initiate the medicine, prescribe, monitor for toxicity and efficacy as described by the shared care framework until the patient is stabilised.
- To ensure the patient or their carer:
 - $\circ~$ Is counselled with regard to the risks and benefits of the medicine.
 - Provide any necessary written information to the patient with regard to the individual medicine including patient information leaflets on individual drugs.
 - Obtain and document informed consent from the patient when any medicines is prescribed for an off-label indication for any condition
- To be familiar with the shared care framework.
- To provide all information to the patient's GP as required by the shared care framework when
 prescribing responsibility is initially transferred and at any subsequent times as necessary for
 safe and effective treatment of the patient.
- To assess the patient regularly as necessary for the duration of therapy.
- To review the patient promptly if required by the GP concerned.
- To meet any additional requirements as required by the individual medicine shared care framework.
- To communicate failure of a patient to attend a routine hospital review and advise the GP of appropriate action to be taken.
- Addition of a second DMD: Following the addition of a new drug to an existing regime covered by a Shared Care Agreement, the Specialist must initiate, prescribe and monitor the

new drug in accordance with the relevant shared care agreement including subsequent review and inform the GP of this. A new Shared Care Agreement must then be initiated for the new drug.

 For <u>Rheumatology patients only - under the care of St Helens and Knowsley Hospitals</u>: where GP chooses Option 1 – Blood test monitoring will remain the responsibility of Rheumatology department via Rheumatology Monitoring System. Rheumatology department takes responsibility for actioning abnormal blood test results. Blood test results will be available to GP via Whiston Pathology ICE (or for GP practices that do not have access to this, via patient hand held blue results card)

Primary Care Responsibilities in Shared Care

• To reply to a written request for Shared Care within 21 days ensuring both copies of the Shared Care Agreement are signed if appropriate.

If agreeing to shared care, the GP is asked to:

- To provide prescribe or manage and monitor the medicine as advised by the Specialist and in line with the individual Shared Care Framework.
- For <u>Rheumatology patients only under the care of St Helens and Knowsley</u> <u>Hospitals</u>: where GP chooses Option 1 – GP to prescribe medication and ensure patient has been attending for blood tests via rheumatology monitoring system and that blood test results are available (via Whiston Pathology ICE system or patient held blue result card blood test monitoring).
- To review the patient as required by the Shared Care Framework
- To make appropriate and contemporaneous records of prescribing and/or monitoring and to note the existence of the Shared Care Agreement on the patient's clinical record. A READ code of "6652 Shared Care- Specialist/GP" can be used.
- To be familiar with the individual Shared Care Framework.
- To report any adverse effects of treatment to the specialist team.
- To inform the Specialist of any relevant change in the patient's circumstances.
- To seek Specialist advice as appropriate.
- To meet any additional requirements as required by the individual Shared Care Framework.
- To respond to Specialist communication relating to any change or addition to the patients treatment covered by the Shared Care Agreement.

Appendix 2:

Disease modifying drugs (DMDs)

Request by Specialist Clinician for the patient's GP to enter into a shared care agreement

<u>Part 1</u>

To be signed by Consultant / Associate Specialist / Specialist registrar or Specialist Nurse (who must be a prescriber)

Date	
Name of patient	
Address	
Patient NHS No	If using addressograph label please attach one to each copy
Patient hospital unit No	
Diagnosed condition	
Dear Dr	
I request that you prescribe	
(1)	
(2)	
(3)	
(4)	

for the above patient in accordance with the enclosed shared care framework.

Last Prescription Issued: / / Next Supply Due: /	/ /
Date of last blood test: / / Date of next blood test: .	11
Frequency of blood test:	
I confirm that the patient has been stabilised and reviewed on	the above regime in
accordance with the Shared Care Framework and Policy.	

I confirm that if this is a Shared Care Agreement for a drug indication which is unlicensed or off label, informed consent has been received.

Details of Specialist Clinicians

Name _	Date

Consultant / Associate Specialist / Specialist Registrar / Specialist Nurse *circle or underline as appropriate

Signature

In <u>all</u> cases, please also provide the name and contact details of the Consultant.

When the request for shared care is made by a Specialist Nurse, it is the supervising consultant who takes medico-legal responsibility for the agreement.

Consultant:	
Contact details:	
Telephone number:	Ext:
Address for return of documentation	
Part 2 To be completed by Pr	imary Care Clinician
I agree to prescribe the enclosed shared care fra	
For <u>Rheumatology patients</u> I would like monitoring to be u	only under the care of St Helens and Knowsley Hospitals undertaken
	Monitoring System Yes / No I by the Rheumatology Team if the patient's GP has not responded to the request for
Option 2 - at GP surgery	Yes / No
GP signature	Date
GP name	Please print

GP: Please sign and return a copy within 21 calendar days to the address above

OR

GP- If you do not agree to prescribe, please delete the section above and provide any supporting information as appropriate below:

St Helens Rheumatology Monitoring System (RMS)


St Helens Rheumatology Department has developed an in-house computerised blood monitoring system for patients on DMARD therapies which has now been running for over 15 years. It was upgraded to a web-based programme in 2009.

Overleaf is a flow chart of this system.

It has a number of advantages over tradition shared care monitoring (where blood tests are taken, checked and transcribed in to patient held monitoring booklet by hand). These include:

- 1) It minimises the number of health professionals involved in the process, reducing the risk of miscommunication
- 2) It ensures prompt action on any abnormality being taken by an experienced rheumatology nurse specialist
- 3) It is an efficient use of human resources using the computer to do the detection of the abnormality
- 4) It reduces risk of human error an abnormal result being overlooked, or inaccurate transcription of blood test result to patient held monitoring booklet.
- 5) It has a robust mechanism for detecting DNAs and enabling the appropriate action to be taken.

However its major disadvantage is that the results of the tests are sent to the patient on a blue card but the prescribing GP is then reliant on either the patient remembering to bring the blue card record of all their blood tests to the surgery when requesting a repeat prescription or the GP checking the results on the Whiston pathology system assuming they have access to this or the GP trusting in our monitoring system (and I appreciate that they may not feel able to do so).



RHEUMATOLOGY MONITORING SYSTEM (RMS) PATHWAY (2018)